Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC. (EXEL)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
20.4(c) 21.67(c) 21.42(c) 21.09(c) 20.87(c) Last
2 838 368 2 800 448 1 807 837 2 179 432 2 311 319 Volume
-0.20% +6.23% -1.15% -1.54% -1.04% Change
More quotes
Financials (USD)
Sales 2018 619 M
EBIT 2018 181 M
Net income 2018 180 M
Finance 2018 348 M
Yield 2018 -
Sales 2019 937 M
EBIT 2019 415 M
Net income 2019 408 M
Finance 2019 778 M
Yield 2019 -
P/E ratio 2018 36,36
P/E ratio 2019 16,28
EV / Sales2018 9,45x
EV / Sales2019 5,77x
Capitalization 6 191 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company.It engages in the developing and commercializing small molecule therapies for the treatment of cancer.The company brands include comertriq and cobimetinib.Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S.... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
04/19EXELIXIS : to Release First Quarter 2018 Financial Results on Wednesday, May 2, ..
AQ
04/16EXELIXIS : to Release First Quarter 2018 Financial Results on Wednesday, May 2, ..
AQ
04/12EXELIXIS : Elects Dr. Maria Freire to Its Board of Directors
AQ
04/11EXELIXIS : to Release First Quarter 2018 Financial Results on Wednesday, May 2, ..
BU
04/11EXELIXIS : Local man helps raise awareness
AQ
04/10EXELIXIS, INC. (NASDAQ : EXEL) Files An 8-K Departure of Directors or Certain Of..
AQ
04/09EXELIXIS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/09EXELIXIS : Elects Dr. Maria Freire to Its Board of Directors
BU
04/05EXELIXIS, INC. : Today’s Research Reports on Trending Tickers: Exelixis and Gale..
AC
04/02IPSEN : announces EMA validation of filing of a new application for additional i..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on EXELIXIS, INC. 
EXELIXIS - 2013
A downturn could form
SELL
More Strategies
Latest Tweets
04/20Michael Morrissey, co-founder of Baby Safe Haven New England, said old faces,.. 
04/20$EBS $SPY $EXEL $BLUE
2
04/20Q1 2018 EPS Estimates for Exelixis $EXEL Increased by Analyst  
04/19SunTrust Banks Brokers Boost Earnings Estimates for Exelixis $EXEL  
04/19$EXEL ALERT: New Exelixis, Inc. SEC Filing From our Stock News Alerts App 
More tweets
Qtime:128
News from SeekingAlpha
04/203 THINGS IN BIOTECH, APRIL 19 : Let's Talk Genito-Urinary Cancer 
04/20Why Investment Wealth-Builders Disdain Big Pharma Stocks Now 
04/18Calithera's CB-839 Fast Track'd for advanced kidney cancer 
04/17JF'S CORE BIOTECH BUYS #11 : Positive News For Several Holdings, A Change To Ben.. 
04/16Roche Stumbles On Combo Trial Halt, Should You Still Buy? 
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | 4-Traders
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 35,3 $
Spread / Average Target 69%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Executive VP, Chief Financial & Accounting Officer
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.-31.35%6 191
GILEAD SCIENCES2.88%98 675
VERTEX PHARMACEUTICALS5.53%41 476
REGENERON PHARMACEUTICALS-15.99%34 613
GENMAB24.15%12 833
BEIGENE LTD (ADR)71.91%9 059